UNH has been the subject of a number of other research reports. Zacks Investment Research downgraded UnitedHealth Group from a buy rating to a hold rating in a report on Tuesday, March 19th. Oppenheimer increased their price objective on UnitedHealth Group from $300.00 to $305.00 and gave the stock an outperform rating in a report on Wednesday, January 16th. Raymond James decreased their price objective on UnitedHealth Group from $310.00 to $265.00 and set a strong-buy rating for the company in a report on Wednesday, April 17th. Bank of America reiterated a buy rating and issued a $290.00 price objective (down previously from $320.00) on shares of UnitedHealth Group in a report on Wednesday, April 17th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $310.00 price objective on shares of UnitedHealth Group in a report on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $291.56.
UNH opened at $221.75 on Thursday. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $212.78 billion, a price-to-earnings ratio of 17.22, a PEG ratio of 1.19 and a beta of 0.79. UnitedHealth Group has a 12-month low of $208.07 and a 12-month high of $287.94.
UnitedHealth Group (NYSE:UNH) last posted its quarterly earnings data on Tuesday, April 16th. The healthcare conglomerate reported $3.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.60 by $0.13. The business had revenue of $60.30 billion during the quarter, compared to the consensus estimate of $59.72 billion. UnitedHealth Group had a return on equity of 25.07% and a net margin of 5.45%. The firm’s quarterly revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.04 earnings per share. On average, equities analysts predict that UnitedHealth Group will post 14.7 earnings per share for the current year.
In related news, Director Richard T. Burke sold 5,000 shares of the stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $257.32, for a total transaction of $1,286,600.00. Following the sale, the director now directly owns 182,454 shares of the company’s stock, valued at $46,949,063.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gail R. Wilensky sold 2,930 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $253.39, for a total value of $742,432.70. Following the sale, the director now directly owns 64,726 shares in the company, valued at $16,400,921.14. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,930 shares of company stock worth $4,587,133. Insiders own 0.87% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in UNH. Oregon Public Employees Retirement Fund boosted its position in shares of UnitedHealth Group by 50,446.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 53,349,795 shares of the healthcare conglomerate’s stock valued at $214,000 after buying an additional 53,244,249 shares during the last quarter. Norges Bank purchased a new stake in shares of UnitedHealth Group during the fourth quarter valued at $2,343,175,000. BlackRock Inc. boosted its position in shares of UnitedHealth Group by 3.1% during the fourth quarter. BlackRock Inc. now owns 69,831,381 shares of the healthcare conglomerate’s stock valued at $17,396,391,000 after buying an additional 2,123,417 shares during the last quarter. Rehmann Capital Advisory Group boosted its position in shares of UnitedHealth Group by 26,088.2% during the third quarter. Rehmann Capital Advisory Group now owns 1,723,185 shares of the healthcare conglomerate’s stock valued at $6,477,000 after buying an additional 1,716,605 shares during the last quarter. Finally, FMR LLC boosted its position in shares of UnitedHealth Group by 1.9% during the fourth quarter. FMR LLC now owns 64,480,003 shares of the healthcare conglomerate’s stock valued at $16,063,258,000 after buying an additional 1,232,189 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Featured Article: Debt-To-Equity Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.